Jiang Liu, PhD
Senior Director, Molecular Oncology
Jiang Liu, PhD, has over 15 years of experience in drug discovery and development, specializing in antibody-based therapeutics, including ADCs, Bispecific, and Fusion Antibodies. He obtained his PhD from Vanderbilt University and conducted post-doctoral research at the University of Southern California. Jiang began his career at Cellerant Therapeutics as a Scientist, focusing on developing ADCs targeting hematopoietic cancer stem cells. After leading two programs to the IND-ready stage, he joined Modmab Therapeutics, where he established a robust single B cell discovery platform and developed pan-FZD agonist/antagonist for various indications. As a Senior Scientist at Atreca, Jiang served as the functional head for in vivo pharmacology programs, developing a variety of animal models for pharmacology and toxicology evaluations. Before joining Aarvik, he was the Senior Director of the Preclinical Department at Kind Pharmaceutical, where he led pre-clinical efforts to develop several ADC therapeutics targeting diverse tumors.